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Leishmania is a widespread trypanosomatid protozoan para-
site causing significantmorbidity andmortality in humans. The
endobiont dsRNA virus LeishmaniaRNA virus 1 (LRV1) chron-
ically infects some strains, where it increases parasite numbers
and virulence in murine leishmaniasis models, and correlates
with increased treatment failure in human disease. Previously,
we reported that 2-C-methyladenosine (2CMA)potently inhib-
ited LRV1 in Leishmania guyanensis (Lgy) and Leishmania bra-
ziliensis, leading to viral eradication at concentrations above 10
M. Here we probed the cellular mechanisms of 2CMA inhibi-
tion, involving metabolism, accumulation, and inhibition of the
viral RNA-dependent RNA polymerase (RDRP). Activation
to 2CMA triphosphate (2CMA-TP) was required, as 2CMA
showed no inhibition of RDRP activity from virions purified on
cesium chloride gradients. In contrast, 2CMA-TP showed IC50
values ranging from 150 to 910M, depending on the CsCl den-
sity of the virion (empty, ssRNA-, and dsRNA-containing). Lgy
parasites incubated in vitro with 10 M 2CMA accumulated
2CMA-TP to 410M, greater than themost sensitive RDRP IC50
measured. Quantitative modeling showed good agreement
between the degree of LRV1 RDRP inhibition and LRV1 levels.
These results establish that 2CMA activity is due to its conver-
sion to 2CMA-TP, which accumulates to levels that inhibit
RDRP and cause LRV1 loss. This attests to the impact of the
Leishmania purine uptake and metabolism pathways, which
allow even a weak RDRP inhibitor to effectively eradicate LRV1
at micromolar concentrations. Future RDRP inhibitors with
increased potency may have potential therapeutic applications
for ameliorating the increased Leishmania pathogenicity con-
ferred by LRV1.
Theneglected tropical disease leishmaniasis is caused by spe-
cies of the genus Leishmania, which are single-celled eukary-
otic parasites transmitted by phlebotomine sand flies (1, 2).
Leishmaniasis occurs in many regions of the world, with more
than 12million cases andmore than 1.7 billion people at risk (1,
3). Three clinical presentations are most common: mild, self-
healing cutaneous lesions (cutaneous leishmaniasis or CL),2
fatal visceral disease, and disfiguring metastatic forms such as
mucocutaneous leishmaniasis (MCL) (4). The factors deter-
mining disease progression and responsiveness to treatment
are unclear, but are thought to be both host- and pathogen-
derived (5, 6).
Many isolates of Leishmania within the subgenus Viannia,
including Leishmania braziliensis (Lbr) and Leishmania guya-
nensis (Lgy), bear Leishmaniavirus, a single-segmented dsRNA
Totivirus known as Leishmania RNA virus 1 (LRV1) (5, 7–9).
Like most other Totiviridae species, LRV1 is neither shed nor
infectious and is inherited vertically (10, 11); indeed, phyloge-
netic evidence suggests that LRV1 strains have persisted and
co-evolved with their Leishmania hosts over millions of years
(10).
Previous work has established that mice infected with para-
sites containing the endobiont LRV1 exhibit greater pathology,
higher parasite numbers, and increased metastasis (12, 13).
These studies benefited from the availability of isogenic LRV1
or LRV1 lines, generated spontaneously or by defined meth-
ods such as RNAi or antiviral drug treatment (14–16).
The role of LRV1 in human leishmaniasis has been more
challenging to establish definitively. When comparing rates of
CL and MCL, some studies find that LRV1 strains generate
more MCL (17–19), whereas others do not (20, 21). These dis-
crepant findings may be explained by other parasite or host
factors known to contribute to MCL pathology (13, 22, 23).
Furthermore, differences in the severity of disease are not
always accurately captured by binary categorization as CL or
MCL. Moreover, co-infections with viruses inducing Type I
interferon responses exacerbate Lgy pathology and metastasis
(24, 25), potentially obscuring the contributions of LRV1.
Importantly, the presence of LRV1 in clinical isolates of Lbr or
Lgy correlates with drug treatment failure and relapses (18, 20),
which could be explained by the increased parasite numbers or
altered host responses predicted from animal models (12, 13,
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26). Overall, there is good reason to postulate a role for LRV1
in increasing disease severity in human leishmaniasis (13),
although many questions remain.
LRV1 follows a typical totiviral life cycle where the dsRNA
viral genome encodes two large overlapping reading frames, the
capsid andRNA-dependent RNApolymerase (RDRP) (Fig. 1A).
First, the dsRNA genome is transcribed by the viral RDRP into
positive-sense ssRNA. As in many totiviruses, the RDRP is
translated via a 1 frameshift, generating a capsid–RDRP
fusion (27–29). The capsid monomers then self-assemble into
immature virions (30), incorporating the positive-sense ssRNA
transcript, which the RDRP then replicates into the mature
dsRNA genome.
Vaccination of mice using the LRV1 capsid results in signif-
icant protection against LRV1 Lgy (31), suggesting that ther-
apies targeting LRV1 specifically might aid in reducing disease
pathology. Previously, we reasoned that the powerful nucleo-
side and nucleobase salvage pathways of Leishmania might
enhance the efficacy of nucleosides analogs targeting the viral
RDRP (15, 32). Accordingly, screening a small library of antivi-
ral nucleosides identified two closely-related adenosine ana-
logs, 2-C-methyladenosine (2CMA) and 7-deaza-2-C-methy-
ladenosine (7d2CMA) (Fig. 1B), which specifically inhibited
LRV1 replication in cultured Leishmania cells (15). These com-
pounds exhibited EC50 values of 3–5 M for viral inhibition,
contrasting with much greater EC50 values for the parasites
themselves. The active compounds rapidly eradicated LRV1
when tested at concentrations above 10M, allowing us to read-
ily create isogenic LRV1 lines (15).
Importantly, these were the first studies showing specific
inhibition of any totivirus. The mechanism of anti-LRV1 activ-
ity was postulated to be through direct inhibition of the LRV1
RDRP by the triphosphorylated form of 2CMA. Here we pro-
vide support for this hypothesis, although the potency of
2CMA-TP for viral inhibitionwas unexpectedly weak. Remark-
ably, viral inhibition was accomplished through hyper-accu-
mulation and retention of 2CMA-TP, arising from the powerful
uptake and metabolic salvage pathways of these purine aux-
otrophs (32). These findings have significant implications for
future efforts aimed toward developing new and more potent
Leishmania virus inhibitors.
Results
Purification and separation of virion populations on CsCl
gradients
RDRP assays were carried out with Lgy strain M4147 LRV1
virions purified by CsCl equilibrium gradient centrifugation (7,
33). After fractionation, virionswere detected and quantified by
their reactivity with an anti-capsid antibody. We reproducibly
observed three overlapping “peaks,” designated low-, medium-,
and high-density (LD,MD, andHD) (Fig. 2). In previous studies
of the yeast L-A Totivirus, similar peaks were shown to corre-
spond to virions that were primarily “empty” or contained
ssRNA or dsRNA, respectively (34, 35). The densities of the Lgy
LRV1 LD,MD, and HD peaks were 1.29, 1.36, and 1.41 g/ml, in
good agreement with the densities of L-A virus particles bear-
ing ssRNA and dsRNA (1.31 and 1.41 g/ml, respectively) (36).
Preliminary data from S1 nuclease digestion of viral RNA from
these fractions were consistent with these assignments.3
In vitro assay of LRV1 RDRP activity
To measure RDRP activity, purified virions were allowed to
incorporate [-32P]UTP in the presence of the other three
nucleoside triphosphates for 1 h, a time sufficient for one round
of viral genome replication (33). RNA was purified and sepa-
rated by native gel electrophoresis, and the products were visu-
alized and quantified. Two products were always found: one
about 5 kb, presumably corresponding to the full-length LRV1
genome, and smaller, heterogeneous products ranging from 0.1
3 J. I. Robinson, unpublished observations.
Figure 1. Leishmania LRV1 replication cycle and inhibitors.A, a schematic
depiction of the LRV1 lifecycle. RNAs are indicated in color ( strand, red;
strand, blue); the dsRNA genome within the mature virion is shown as
straight lines, whereas ssRNAs are shown as jagged lines. The viral RDRP (black
trapezoid) is shown fused to a capsid monomer (white circle), as the RDRP is
generated through frameshift translation (27–29). B, chemical structures of
adenosine, 2-C-methyladenosine, and 7-deaza-2-C-methyladenosine.
Figure 2. Distribution of viral capsid protein across a CsCl density gradi-
ent. Clarified parasite lysates were separated on a CsCl density gradient and
the relative amounts of viral capsid protein in each fraction were measured
(black triangles; see “Experimental procedures”). The density of each fraction
(gray circles) was measured with an Abbe refractometer. Data for one repre-
sentative gradient are shownout of the 7 performed. The low-,medium-, and
high-density “peak” fractions (LD, MD, and HD) taken for RDRP assays, are
labeled.
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to 0.5 kb, which we considered abortive transcripts (Fig. 3A).
Neither extending the incubation time nor increasing the con-
centration of UTP significantly altered the profile obtained.3
Importantly, neither full-length nor small products were pro-
duced by corresponding preparations fromLRV1-negative par-
asites (Fig. 3B).
2CMA-TP specifically inhibits viral RDRP activity
Incubation of the three LRV1 fractions with 2CMA-TP
reduced synthesis of both the full-length and small RDRP prod-
ucts (Figs. 3–5). The synthesis of each product was quantitated
and normalized to that obtained with drug-free controls. IC50
values were calculated by fitting the inhibition data with a logis-
tic dose-response curve (Table 1). These ranged from 150 M
for full-length product synthesis by LD virions to 910 M for
small products synthesized by HD virions (Table 1, Figs. 3 and
4). These IC50 valueswere unexpectedly high, greatly exceeding
the extracellular concentration of 2CMA shown previously to
cause 50% inhibition of LRV1 abundance (3M) (15). This did
not arise artificially from 2CMA-TP degradation during the
Figure 3. Radiolabeled RNAs produced by purified Lgy LRV1 RDRP in
vitro. A, RDRP activity in LD, MD, and HD fractions (Fig. 2) was assayed by
[-32P]UTP incorporation, as described under “Experimental procedures.”
Radiolabeled RNAs were run along-side pure [-32P]UTP on a native agarose
gel. The full-length and small RDRP products are labeled for reference. B,
RDRP reactions were performed in the presence of 0, 10, 30, 100, 300, or 600
M 2CMA-TP. As a negative control, the RDRP reaction was run using a mock
HD fraction isolated from LRV1 Lgy parasites. A representative titration
using the HD fraction is shown here out of the 4 HD fraction titrations
performed.
Figure 4. 2CMA-TP inhibition of RDRP activity of purified Lgy LRV1 viri-
ons. The amounts of full-length or small RDRP products were quantified and
then normalized to the amount of product formed in the absence of 2CMA-
TP. The averages and S.D. values (calculated with Microsoft Excel) from three
LD virion titrations () and four HD virion titrations (Œ) are shown. Dose-
response curves for LD (dotted line) andHDvirions (solid line)were fittedusing
the drc package in R (68). A, plot of full-length RDRP products. B, plot of small
RDRP products. MD virions showed intermediate profiles3 (Table 1).
Figure 5. Specificity of Lgy RDRP inhibition by 2CMA-TP relative to
2CMA and dATP. RDRP reactions were performed for 1 h in the presence
of 1 mM 2CMA, 600 M dATP, or 600 M 2CMA-TP. The amount of full-
length (top panel) and small products (bottom panel) were measured and
normalized to untreated control reactions. Individual values are shown for
two experiments (with 1 or 2 technical replicas) and themeans aremarked
with horizontal lines.
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assay, as HPLC tests of RDRP reactions showed only 3.7 0.6%
(n 3) loss of 2CMA-TP.
As anticipated, 2CMA did not measurably inhibit RDRP
activity when tested at concentrations up to 1000 M (Fig. 5).
Similarly, dATP, which lacks both the 2-hydroxyl and methyl
groups of 2CMA (Fig. 1B), failed to inhibit RDRP activity at the
highest concentration tested (600 M; Fig. 5); nor in limited
tests did 600–1000MTTP inhibit.3 These data show that high
concentrations of a nonsubstrate nucleoside triphosphate do
not inhibit RDRP activity nonspecifically. Together, these data
suggest that despite its relatively low potency, under these assay
conditions 2CMA-TP inhibition of LRV1 RDRP activity was
specific.
2CMA activation to 2CMA-TPwithin parasites
To account for the relative sensitivity of Lgy LRV1 within
cells to 2CMA treatment compared with the insensitivity of
LRV1 RDRP activity to inhibition by 2CMA-TP, we hypoth-
esized that parasites must acquire and activate 2CMA, accu-
mulating high 2CMA-TP concentrations. We developed an
HPLC protocol capable of resolving synthetic 2CMA-TP
from natural ribonucleotides and the internal standard,
dGTP (Fig. 6, A and B; a small peak presumed to be
2CMA-DP was also observed). Although dGTP occurs natu-
rally, its intracellular concentration of5 M is well below the
limit of detection for this assay and thus does not interfere with
its use for this purpose (37). Standard mixtures were then used
to generate a calibration curve relating peak area to 2CMA-TP
amount.
We next evaluated several protocols for extracting parasite
nucleotides and determined that extraction with 1:1 acetoni-
trile:water performed best, as judged by recovery of the added
dGTP standard (“Experimental procedures”). We then com-
pared the nucleotide profiles of LRV1 Lgy grown in the pres-
ence or absence of 10 M extracellular 2CMA for 20 h, a time
corresponding tomore than two rounds of parasite replication.
Under these conditions, we observed a peak co-eluting with
synthetic 2CMA-TP that was absent from untreated parasites
(Fig. 6B). This established the parasite’s capacity to activate
2CMA to 2CMA-TP.
Time and external 2CMA concentration dependence of
2CMA-TP accumulation
Leishmania cell volumes vary somewhat depending on the
culture’s growth phase (38). To calculate the intracellular
2CMA-TP concentration, we therefore determined the average
volume of Lgy parasites under our assay conditions. In logarith-
mic growth phase, parasite volumes averaged about 23 femto-
liters (“Experimental procedures”).
We measured the intracellular concentration of 2CMA-TP
as a function of time of incubation with 10 M external 2CMA.
Within 1.5 h, 2CMA-TP levels had risen to concentrations
comparable with the minimal RDRP IC50 levels (Fig. 7A), and
had reached maximal levels by 8 h.
We thenmeasured the intracellular 2CMA-TP levels follow-
ing growth in varying levels of 2CMA for 20 h (Fig. 7B). The
concentrationswere chosen to span a range fromnoninhibitory
(1M) to that sufficient to eradicate LRV1 entirely (10M) (15).
Over this range of concentrations, internal 2CMA-TP levels
exceeded external 2CMA concentrations by 40- to 80-fold (Fig.
7B).
When propagated in the subinhibitory dose of 2CMA (1M),
the intracellular 2CMA-TP concentration was 78 9 M (Fig.
7B, n  4), well below the minimal IC50 for RDRP inhibition
(150 M for full-length products from LD virions; Table 1).
When treated with 3 M external 2CMA, the EC50 for LRV1
inhibition, intracellular 2CMA-TP levels rose to 152  43 M
(n 4), comparable with the minimal RDRP IC50. Finally, cells
propagated in 10 M external 2CMA reached an intracellular
2CMA-TP concentration of 410  110 M (n  4) (Fig. 7B),
well in excess of the minimum IC50 for RDRP inhibition. Thus,
with increasing external 2CMA, the steady-state levels of intra-
Table 1
Effect of 2CMA-TP on Lgy LRV1 RDRP activity
IC50 values and 95% confidence intervals for the inhibition of full-length and small
RDRP product synthesis were calculated by simultaneously fitting RDRP inhibition
data for each RDRP product and virion population to logistic dose-response curves
(drc package in R (68)). Because the RDRP activity was normalized with no activity
set as zero, we fixed the minimum parameter to zero. The influence of RDRP prod-
uct type and virion population on the IC50 values was estimated by fitting dose-
response curves while combining all RDRP products or virion populations. Com-
paring these submodels to the full model using analysis of variance (68) showed that
virion type contributes significantly to the goodness-of-fit (p 0.001), whereas the










Full-length 150 (90–210) 250 (100–400) 420 (310–540)
Small 250 (160–330) 640 (300–980) 910 (620–1200)
Figure 6. Lgy M4147 LRV1 parasites synthesize 2CMA-TP. A, standard
mixture of dGTP, ATP, and 2CMA-TP establishing the HPLC elution profile of
2CMA-TP relative to dGTP, the exogenous internal standard (endogenous
cellular dGTP concentrations are well below the limit of detection). The small
peak eluting between dGTP and ATP is presumed to be 2CMA-DP. B, detec-
tion of 2CMA-TP in Lgy incubated with 10 M 2CMA for 20 h (blue line). An
extract from cells grown without drug (gray line) is provided for comparison.
To correct for variation in extraction efficiency and HPLC elution times, Lgy
samples had 7 nmol of dGTP spiked in immediately prior to extraction.
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cellular 2CMA-TP rose progressively to values exceeding the
minimal RDRP IC50, which in turn corresponded reasonably
well to the observed effects on LRV1 inhibition.
Parasites retain 2CMA-TP for an extended period following
2CMA removal
Once phosphorylated by cells, some nucleoside analogs are
retained for an extended period as triphosphates, thereby con-
tributing significantly to drug efficacy (39). To assess this, Lgy
parasites were incubated for 20 h in 10 M 2CMA, washed, and
resuspended in drug-free medium, after which intracellular
2CMA-TP levels weremeasured and corrected for parasite rep-
lication (Fig. 7C). Even after 8 h, 2CMA-TP levels remained at
or above the minimal RDRP IC50. Indeed, the persistence of
intracellular parasite 2CMA-TP greatly exceeded that of serum
2CMAmeasured in mammalian models (40).
A quantitative simulation of RDRP and virus inhibition
We asked whether a simple computational model using the
relative rates of parasite and viral replication under conditions
of drug treatment could quantitatively simulate the experimen-
tal data above. We developed a model employing Gibson and
Bruck’s next reactionmodification toGillespie’s stochastic sim-
ulation algorithm (41), which directly simulates the occurrence
of individual events over time by picking the next event time
froman associated probability distribution (“Experimental pro-
cedures”; supporting File S2).
In this model, the relevant parameters were parasite and
virus replication rates. We used the experimentally-measured
parasite population doubling time of 7.5 h and assumed that in
the absence of drug pressure the relative parasite and virus rep-
lication rates were identical. Simulations began with an initial
population of 1000 cells, a number large enough that repeated
simulations deviated1% from each other. The simulated par-
asites each initially contained 16 LRV1 particles, consistent
with prior measurements of virus numbers (15). Using these
conditions, the simulation correctly maintained the LRV1 pop-
ulation over time at an average of 16 virions per parasite in the
absence of drug pressure (Fig. 8).
The effect of 2CMAwas then modeled by adjusting the ratio
of LRV1 to parasite replication rates (RV:RP). Importantly, at
concentrations relevant to these studies, 2CMA has little effect
on the growth of the parasite itself (15). After setting RV:RP to
1:2, 1:3, or 1:4, LRV1 was now rapidly lost (Fig. 8). Comparison
of the simulations with RV:RP of 1:3 or 1:4 showed close corre-
spondencewith the experimentally-measured rate of LRV1 loss
Figure 7. L. guyanensis parasites accumulate high levels of 2CMA-TP.
Intracellular 2CMA-TP was extracted and quantified by HPLC (Fig. 6; File S2)
and its concentration was calculated using the measured cell volume of 23
femtoliters under these conditions (“Experimental procedures”). Each repli-
cate (gray circles) was obtained from a separate 5-ml culture grown in Schne-
ider’s medium. Averages and S.D. (black diamonds; calculated in Microsoft
Excel) are also plotted for each time point or condition. For reference, the
minimumRDRP IC50 is marked on each graph (green dashed line). A, 2CMA-TP
accumulation in parasites measured over time. Lgy parasites were incubated
in 10 M 2CMA for the indicated periods and 108 cells were harvested for
analysis. This experiment was performed twice. Intracellular 2CMA-TP con-
centrations at equilibrium after 20 h of incubation with 10 M 2CMA are also
plotted (gray triangles). B, steady-state concentrations of 2CMA-TP vary with
2CMAdose. Lgyparasitesweregrown for 20h in thepresenceof the indicated
concentrations of external 2CMA prior to analysis. This experiment was
repeated four times. The fold-concentration of intracellular 2CMA-TPwas cal-
culated relative toextracellular 2CMAdose (bluediamonds). For reference, the
EC50 for LRV1 inhibition in parasites is marked on the X axis (black arrow). C,
retention of 2CMA-TP following removal of 2CMA. LRV1 Lgy M4147 para-
siteswere incubated for 20h in thepresenceof 10M2CMA; at that time, cells
were harvested,washed, and resuspended in drug-freemedium. Intracellular
2CMA-TP levels were determined after incubation for the indicated times. To
correct for 2CMA-TP dilution due to parasite replication, 2CMA-TP concentra-
tions were multiplied by the fold-population growth due to 2CMA removal
(about 1.4-fold over the course of the experiment). This experiment was
repeated twice using two independent cultures per time point (n  4; gray
circles). Averages and S.D. (black diamonds; calculated in Microsoft Excel) are
also plotted for each time point. Because some time points were collected at
slightly varying times, these were averaged for plotting in the figure.
Figure 8. Gillespie simulation of LRV1 loss during 2CMA treatment. Plots
of simulated, theoretical, and experimental results showing the number of
LRV1 virions per cell as a function of cell doubling are shown. Gillespie simu-
lations were performed assuming relative inhibition of LRV1 and parasite
replication (RV:RP) to be between 1:1 and 1:4 are depicted by blue lines. These
lines represent averages and S.D. of 6 identical simulations (Excel). A theoret-
ical plot is show (gray dotted line) for total inhibition of viral replication with
ideal 2-fold viral dilution per population doubling time. Two experimental
data sets from Kuhlmann et al. (15) measuring LRV1 loss during 2CMA treat-
ment are shown as black dashed lines.
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under 2CMA inhibition (15) (Fig. 8; solid lines, simulation;
dashed lines, experimental).
To compare these predictions with our experimental data on
parasite replication and RDRP inhibition, we made an initial
simplifying assumption that the primary determinant of LRV1
replication would be the lowest RDRP 2CMA-TP IC50 value
(150 M, for full-length product synthesis by LD virions; Table
1; Fig. 4A). Because RDRP inhibition would reduce viral RNA
levels within infected cells, RDRP activity would likely become
rate-limiting at high 2CMA-TP concentrations. We then cal-
culated the 2CMA-TP concentrations required to give RV:RP of
1:2, 1:3, or 1:4. Importantly, at 10Mextracellular 2CMA, intra-
cellular 2CMA-TP is 410 M, and RV:RP was calculated to be
1:3 (Fig. 8). Thus the simulation and experimental data are in
good agreement about the quantitative and qualitative aspects
of RDRP inhibition and viral loss. This suggests that despite the
potential complexity of viral replication, the system behaves as
RDRP activity is rate-limiting for viral replication and that our
in vitro measurements of 2CMA-TP inhibition are consistent
with our in vivo measurements of viral elimination time
courses.
Discussion
Previously, we showed that two 2-C-methyladenosine ana-
logs selectively inhibit the replication of Lgy and Lbr LRV1 but
have significantly less effect on the parasite growth rates. These
compounds were the first such inhibitors to be described for
any totivirus (15). There, the mechanism of action was pre-
sumed but not shown to follow the classic antiviral nucleoside
paradigm of uptake, conversion to the nucleoside triphosphate,
and inhibition of the viral RDRP. In this study, we provide evi-
dence that this is in fact the case for Lgy LRV1 inhibition fol-
lowing 2CMAtreatment. Importantly, the ability of the parasite
to accumulate high levels of 2CMA-TP (Fig. 7) was strongly
correlated with viral elimination at concentrations above 3 M
external 2CMA (15). These data provide key information for
the design of other improved LRV1 inhibitors with greater
potential for use as therapeutics.
We first established an assay for RDRP activity from purified
virions, separated on CsCl gradients to obtain virions in differ-
ent stages of maturation (Figs. 1–3). RDRP activity depended
on the presence of LRV1 and yielded two major products, cor-
responding to the full-length viral genome as well as a hetero-
geneous collection of small and presumably abortive tran-
scripts (Fig. 3). Quantitative analysis showed that the IC50
values for full-length product synthesis were somewhat lower
than thosemeasured for small product synthesis (p 0.05), and
significantly less for low-density virions than high (p  0.001;
Table 1). These may reflect the intrinsic sensitivities of the
RDRP activity within mature and immature viral particles,
perhaps related to the distinct transcriptase/positive-strand
(mRNA) and replicase/negative-strand synthesis activities.
This is the first such report for totiviruses, for which antiviral
drugs have only recently been reported (15). Differential effects
on replicase versus transcriptase activity have also been seen in
reoviruses, where ribavirin triphosphate inhibits replicase but
not transcriptase activity (42). Our studies were constrained by
two factors: first, the virion-based RDRP assay depends on
native RNA substrates, and second, the virion-containing frac-
tions usedwere not homogeneous (Fig. 2). This prevented clean
separation of RDRP transcription and replication activities, and
precluded the use of tightly-controlled initiation and elonga-
tion assays, required for determination of the precise mecha-
nism of RDRP inhibition by 2CMA-TP. Future studies with
purified RDRP and defined RNA substrates will be required to
fully elucidate the mechanism of action of 2CMA-TP.
2CMAwas completely inactive for RDRP inhibition, as were
dATP or TTP, structurally similar nonsubstrate nucleoside
triphosphates (Fig. 5). Activation to triphosphate form is com-
mon and often rate-limiting among nucleoside analog drugs
(43–45). It was also shown previously that the triphosphate
form of 2CMA, but not the analog itself, is active against the
hepatitis C virus RNA polymerase (46).
Despite the ability of 2CMA to clear LRV1 from parasites
grown in micromolar concentrations of drug (15), 2CMA-TP
inhibition of LRV1RDRP activitywas not very potent, with IC50
values ranging upwards of 150 M (Table 1). We resolved this
discrepancy by showing that the parasites avidly scavenged
2CMA from the medium and efficiently converted it to the
active triphosphate form (Fig. 6), reaching intracellular
2CMA-TP concentrations more than 40-fold that of extra-
cellular 2CMA (Fig. 7). This likely reflects the fact that as
purine auxotrophs, Leishmania parasites must avidly scav-
enge all naturally occurring purines from their environment,
through a combination of powerful transporters and meta-
bolic interconversions (32). One particularly important step
for 2CMA and related inhibitors may be adenosine kinase
(47, 48), which may mediate the initial and often rate-limit-
ing phosphorylation of antiviral nucleosides (44, 49). Strong
accumulation of toxic anti-leishmanial purines has also been
noted in earlier studies (50, 51). Thus the salvage pathway
converts 2CMA into a potent tool for eliminating the virus.
Importantly, the accumulated levels of intracellular 2CMA-TP
closely matched the consequences of RDRP inhibition and LRV1
loss. When grown in 10 M external 2CMA, internal 2CMA-TP
levels greater than 400 M were attained, well over the minimal
LRV1 RDRP IC50 (Table 1). In contrast, at 1 M external 2CMA,
internal 2CMA-TP concentrations were only 80 M, well below
that needed for RDRP inhibition, and little effect was seen on
LRV1 levels (15). These experimental observations were corrobo-
rated using Gillespie (52) simulation to model LRV1 loss (Fig. 8).
Our studies did not examine other potential 2CMA-TP targets
suchas the capsid endonuclease (53–57) andcouldnotdiscern the
exactmechanismofRDRP inhibitionby 2CMA-TP.Nevertheless,
these analyses show that the eliminationof LRV1by2CMAcanbe
largely explained through the direct inhibition of LRV1 RDRP
activity by 2CMA-TP.
Previously, we proposed that treatments targeting LRV1
could be used therapeutically to ameliorate the severity of Lgy
and Lbr infections (15, 31). 2CMA-TP accumulates rapidly to
inhibitory concentrations within 1–2 h of 2CMAexposure, and
once formed, is retained at inhibitory concentrations for	8 h
(Fig. 7). This suggests that a relatively short period of treatment
may lead to a prolonged period of viral inhibition. In animal
models, 2CMA has a short serum half-life, which precludes its
use in humans or animals. The serum half-life of 7d2CMA,
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however, is markedly longer (0.3 versus 1.6 h (58)). Interest-
ingly, 7d2CMA shows an EC50 against Zika virus in cultured
mammalian cells of about 10 M, and dosing regimens have
shown significant inhibition in animal models (59, 60). This
suggests it might likewise be possible to achieve inhibition of
LRV1 in vivo using 7d2CMA.
In future work, one priority will be the development of anti-
LRV1 agents with improved potency. Preliminary studies
expressing a promiscuousHSVTK genewithin Leishmania did
not increase the spectrumof activity significantly for those ana-
logs tested from our previous study (15),3 suggesting that the
lack of activity may reflect failure to inhibit the LRV1 RDRP
itself rather than insufficient activation to triphosphates. Simi-
larly, we found that several immucillins shown previously to
inhibit Leishmania nucleoside hydrolases (Immucillin A,
DADMe-Immucillin A, Immucillin H, and DADMe-Immucil-
lin H (61, 62)) had little effect on the potency of 2CMA.3While
these immucillins are nucleoside analogs, they showed no inhi-
bition of LRV1 levels when tested at concentrations up to 100
M.3
Additional priorities will be identifying compounds with
more favorable pharmacokinetics and minimal toxicity against
the mammalian host cell. Thus, efforts focusing on improved
potency against the RDRP activity itself may prove most fruit-
ful. Ourwork now sets the stage for future studies exploring the
possibility that improved LRV1-targeted therapiesmay amelio-
rate the pathology of those Leishmania species and strains that
bear this fascinating virus.
Experimental procedures
Parasite strains andmedia
Luciferase-expressing isogenic clones of L. guyanensis strain
M4147 (MHOM/BR/75/M4147)were utilized for these studies.
LRV1 clone LgyM4147/SSU:IR2SAT-LUC(b)c3 and LRV1
clone LgyM4147/pX63HYG/SSU:IR2SAT-LUC(b)c4 were
described previously (63). For some experiments a LgyM4147/
LRV1 line expressing GFP (LgyM4147/SSU:IR2SAT-
LUC(b)c3/SSU:IR3HYG-GFP(b)) was used (provided by E.
Brettmann). Schneider’s medium (Sigma) was prepared follow-
ing the manufacturer’s instructions, supplemented with 10%
heat-inactivated FBS, 0.76 mM hemin, 2 g/ml of biopterin, 50
units/ml of penicillin, and 50 g/ml of streptomycin, and
adjusted to a final pH of 6.5. M199 medium was prepared with
2% heat-inactivated FBS, 2% filter-sterilized human urine, 0.1
mM adenine, 1 g/ml of biotin, 5 g/ml of hemin, 2 g/ml of
biopterin, 50 units/ml of penicillin, 50 g/ml of streptomycin,
and 40mMHEPES, pH 7.4 (64). No significant differences were
observed in the properties of virus preparations from either
medium. Cells were counted using either a hemocytometer or a
Coulter counter (BD Bioscience).
Purification and fraction of virions on CsCl gradients
Parasites were grown to early stationary phase in M199 or
Schneider’s medium (3
 107 or 9
 107 cells/ml, respectively).
1
 1010 cells were pelleted at 2200
 g for 15 min at 4 °C and
washed twicewith 10ml ice-coldTMNbuffer (100mMTris, pH
7.5, 50 mMMgCl2, 1.5 M NaCl). Cells were then resuspended in
1 ml of ice-cold lysis buffer (TMN buffer plus 1 mM DTT, 1

Complete protease inhibitor mixture (Roche Applied Science)
and 1% (v/v) Triton X-100), homogenized by pipetting 10–12
times with a 1-mlmicropipette, and incubated on ice for 20–30
min. Lysis was completed by passing the mixture repeatedly
through a 27-guage needle, after which it was clarified by cen-
trifugation at 15,000 
 g for 10 min at 4 °C. Density gradients
were prepared by thoroughly mixing the clarified lysates with
enough 10
TMNbuffer, saturatedCsCl, and distilledwater to
make 12 ml of solution at a final density of 1.35 g/ml (2.82 M
CsCl). Gradients were spun in a pre-chilled SW41Ti rotor
(Beckman) at 32,000 rpm and 4 °C for72 h. Twelve 1-ml frac-
tions were recovered immediately from each gradient using a
density gradient fractionator (ISCO).
The distribution of capsid protein across each gradient was
determined by binding of 50-l aliquots of each fraction to a
nitrocellulose membrane using a Mini-fold II Slot-Blot System
(Schleicher & Schuell, Keane, NH). The membrane was incu-
bated on a rollerwith blocking buffer (2%nonfat powderedmilk
in PBS) for 1 h, then stained with 1:2500 rabbit anti-capsid
antibody (65) in blocking buffer plus 0.2% Tween 20 (TWEEN
buffer) for another hour. The membrane was then washed 3
times for 5 min in 1
 PBS plus 0.1% Tween 20 (PBST). Mem-
branes were next incubated in TWEEN buffer for 1 h with
1:10,000 goat anti-rabbit antibodies conjugated to IRDye 680
(LiCor Biosciences). Finally, the membranes were washed 3
times in PBST and once in PBS.Membranes were scanned with
an Odyssey IR Imaging System (LiCor Biosciences). The den-
sity of each fraction was measured by taking its refractive index
with anAbbe refractometer (Bausch and Lomb) and converting
to density using published formulas (66). Gradient fractions of
interest (Fig. 2) were dialyzed twice against 1
 TMN and once
in 1
 TMN plus 20% glycerol (4 °C), reaching CsCl concentra-
tions less than 2 M. Fractions were flash frozen and stored at
80 °C prior to use.
RDRP assay
RDRP activity of purified virions was measured using an
[-32P]UTP incorporation assay described previously (33).
Briefly, 20-l reactions contained 10mMTris-HCl (pH7.5), 150
mMNaCl, 3 mMMgCl2, 4 mMDTT, 50M each ATP, CTP, and
GTP, 20 Ci of [-32P]UTP, and 10 l of virions. Reactions
were incubated at room temperature for 1 h and quenched by
addition of 350 l of TRIzol (Ambion). A corresponding gradi-
ent fraction from LRV1 parasites was included as a negative
control in each set. RNA was purified using a Direct-Zol RNA
miniprep kit (Zymo Research) and run on a native 1.2%
agarose–TAE gel in a vertical gel apparatus (Owl Scientific)
along with dsDNA sizing standards. The standards lane was
excised and stained with ethidium bromide, whereas the radio-
labeled products were detected by exposing an imaging plate
for 24 h and reading it with a FLA-5100 phosphoimager (Fuji).
The amount of radiolabeled UTP in each RDRP product was
quantified using the gel analysis tool in FIJI/ImageJ (67). Equiv-
alent regions from the negative control reaction were also inte-
grated to calculate the background (Fig. 3).
To study inhibition of the viral RDRP by 2CMA-TP, varying
amounts of the compound were added to standard RDRP reac-
tion mixtures. 2CMA-TP was custom synthesized by Jena Bio-
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science, and its identity was confirmed using electrospray ion-
ization with a Fourier transformmass spectrometer in negative
ion mode (Thermo Scientific). The stock concentration of
2CMA-TP was calculated by UV absorption at 260 nm, assum-
ing that its molar extinction coefficient was identical to ATP.
To measure the amount of 2CMA-TP, which is nonspecifically
hydrolyzed over the course of an RDRP reaction, mock reac-
tions were run using LRV1 gradient fractions, cold UTP, and
300 M 2CMA-TP. The 20-l reactions were diluted to 80 l
with distilled water and immediately analyzed by HPLC as
described below.
To estimate IC50 concentrations for each virion population
andRDRPproduct, the quantifiedRDRP activity datawere nor-
malized to untreated and LRV controls and fitted to logistic
dose-response models. Fitting was performed and 95% confi-
dence intervals were estimated using the “drc” package in the R
statistical language (68).
Measurement of parasite volumes
Cultures ofWT or GFP-expressing LRV1 LgyM4147 were
seeded at 2 
 105 cells/ml and analyzed when they reached
early, mid, or late log phase. From each sample, one aliquot was
analyzed by light scattering on a flow-cytometer, whereas
another was immobilized by treatment with 20 mM sodium
azide and imaged by spinning-disk confocal microscopy (69).
Cell volumes were calculated using a custom ImageJ script (67)
(supporting File S1). A standard curve relating forward scatter-
ing intensity to measured volume was developed from these
data. Forward scattering intensity of parasites in our assay con-
ditions was then measured and used to estimate the intracellu-
lar parasite volume.
Nucleotide extraction from Leishmania parasites
For each sample, 108 cells were collected by centrifugation at
2,200
 g, 4 °C for 5 min, re-suspended in 1 ml of ice-cold PBS
and re-centrifuged. The cell pellet was gently re-suspended in
100 l of ice-cold 0.5
 PBS plus 7 nmol of dGTP as a recovery
and elution standard. Cells were immediately lysed by rapidly
re-suspending in 900 l of ice-cold 5:4 acetonitrile:water mix-
ture (70) and vortexing continuously for 5min at 4 °C. Insoluble
debris was pelleted at 16,000 
 g for 5 min and the clarified
extract was transferred to a fresh tube. The solvent was
removed by evaporation in a Savant SpeedVac concentrator
(Thermo Scientific) with the heater off and the vacuum pump
refrigeration on. Samples were re-suspended with 80 l of dis-
tilled water, flash frozen, and stored at 80 °C prior to HPLC
analysis.
HPLC separation of nucleotides
Cell extracts were clarified by centrifuging for 2 min at
16,000
 g. Nucleoside di- and triphosphates were separated by
isocratic HPLC as previously described (71). Briefly, a 20-l
aliquot of clarified extract was injected onto a Zorbax SB-C18
column (5 m particle size, 250
 4.6 mm, Agilent) and eluted
at 1 ml/min with 150 mM KH2PO4 (pH 6.0), 4.2 mM tetrabutyl-
ammoniumhydroxide, and 5.4%methanol. Eluting compounds
were monitored by UV absorbance at 254 nm (Fig. 6). The elu-
tion times of nucleoside triphosphates as well as 2CMA and
2CMA-TP were determined by running them individually. A
minor peak present in each standard was presumed to repre-
sent the diphosphate form of that nucleoside. A mixture con-
taining 200 M ATP, GTP, CTP, UTP, and dGTP was used
periodically to assess column performance. Peak areas were
integrated using Millenium32 software (Waters). Varying
amounts of ATP, 2CMA-TP, and dGTP standards were used to
construct a calibration curve relating peak areas to compound
amounts. Peak areas varied linearly with nucleotide amounts
injected down to 50 pmol.
Gillespie simulation of LRV1 inhibition
We modeled the effects of 2CMA treatment on LRV1 using
the next-reaction modification to the Gillespie algorithm (a
more detailed description as well as code is provided in sup-
porting File S2) (41). The parameters used to define the system
were as follows: number of parasites, number of virions per
parasite, parasite growth rate, and virus replication rate. All
simulations were initialized with 1000 parasites and 16 virions
per cell. Each cell and virus was assigned an amount of time
remaining until it divided or replicated, respectively. Because
these delay times were composed of an unknown but large
number of elementary chemical reactions, they were selected
from Gaussian distributions about the mean parasite division
and virion replication times, rather than the Poisson distribu-
tions used for elementary reactions (41, 52). At each step, the
event with the shortest time remaining was selected, the simu-
lation time incremented, and the model updated accordingly.
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